JnJ seeks USFDA nod of Stelara for pediatric Crohn's disease Ruchika Sharma18 Jun 2025 11:58 AM ISTHorsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA (ustekinumab) for the...
Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek Ruchika Sharma26 May 2025 11:37 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has...
Icotrokinra results show significant skin clearance in patients with difficult to treat scalp, genital psoriasis: JnJ Ruchika Sharma12 May 2025 10:30 AM ISTSpring House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the...
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Dr. Divya Colin4 May 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to...
Revise Phase III protocol: CDSCO Panel Tells Mankind Over Roflumilast Cream Dr. Divya Colin27 April 2025 5:45 PM ISTNew Delhi: Responding to the proposal presented by Mankind Pharmaceutical to manufacture and market selective phosphodiesterase-4 inhibitor...
Psoriasis Patients at Higher Risk of Metabolic and Cardiovascular Conditions, Study Shows Medha Baranwal20 March 2025 9:00 PM ISTChina: A recent study analyzing hospitalized patients in China has highlighted the complex comorbidity patterns associated with moderate-to-severe...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 3:42 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Tildrakizumab Sustains Long-Term Efficacy for Scalp Psoriasis Treatment, reveals research Dr Riya Dave1 Jan 2025 8:15 PM ISTResearchers have established that tildrakizumab, an anti-interleukin-23 p19 antibody, can be used to maintain long-term efficacy and safety for...
New Clinical Trial Supports QX004N's Safety and Effectiveness for Patients With Plaque Psoriasis Medha Baranwal25 Dec 2024 8:30 PM ISTChina: A new randomized clinical trial has demonstrated that QX004N, a humanized anti-IL-23 monoclonal antibody, offers superior safety and efficacy...
